Hereditary Breast Cancer: Practical Pursuit for Clinical Translation
- 545 Downloads
The benefits of a skillful medical history and histologic confirmation of relevant pathology are potentially lifesaving. Appropriately directed DNA testing based on these initial steps provides an opportunity for clinical translation into a cancer prevention program targeted to family members. Unfortunately, cancer prevention strategies that are based on genetics are frequently overlooked or underestimated in the overall practical management of patients at high risk for breast cancer as well as integral cancers that constitute a hereditary breast cancer syndrome. DNA testing, particularly for BRCA1 and BRCA2 in hereditary breast–ovarian cancer syndrome and p53 in the Li-Fraumeni syndrome, and many other syndromes is commercially available for inclusion in a cancer control program and merits attention in this major public health problem. It is clear that the time and effort expended for a hereditary cancer syndrome diagnosis may significantly reduce both morbidity and mortality in breast cancer. We have found that genetic counselors can partner with the clinical physicians and make significant contributions to this labor-intensive effort.
This work was supported by revenue from Nebraska cigarette taxes awarded to Creighton University by the Nebraska Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the State of Nebraska or the Nebraska Department of Health and Human Services. H.L.’s work is partially funded through the Charles F. and Mary C. Heider Chair in Cancer Research, which he holds at Creighton University.
- 1.International Agency for Research on Cancer. Globocan 2008. http://www-dep.iarc.fr/.
- 11.Lynch HT, Marcus JN, Lynch J, Snyder CL, Rubinstein WS. Breast cancer genetics: syndromes, genes, pathology, counseling, testing, and treatment. In: Bland KI, Copeland EM III, editors. The breast: comprehensive management of benign and malignant disorders. 4th ed. Philadelphia, PA: Saunders; 2009. p 371–415.Google Scholar
- 12.Watson P, Narod SA, Fodde R, et al. Carrier risk status changes resulting from mutation testing in hereditary nonpolyposis colorectal cancer and hereditary breast–ovarian cancer. J Hum Genet. 2003;40:591–6.Google Scholar
- 13.Lynch HT, Marcus JN, Watson P, Lynch J. Familial breast cancer, cancer family syndromes, and predisposition to breast neoplasms. In: Bland K, Copeland EM, editors. The breast. Philadelphia: Saunders; 1991. p. 262–91.Google Scholar
- 14.Marcus J, Watson P, Linder-Stephenson L, Conway T, Page D, Lynch H. The pathobiology of BRCA1-linked and -unlinked hereditary breast cancer (HBC) (abstract). Mod Pathol. 1994;7:18A.Google Scholar
- 16.Marcus J, Page D, Watson P, Conway T, Lynch H. High mitotic grade in hereditary breast cancer (abstract). Lab Invest. 1988;56:61A.Google Scholar
- 20.Stalsberg H, Thomas DB, Noonan EA. The WHO collaborative study of neoplasia and steroid contraceptives. Histologic types of breast carcinoma in relation to international variation and breast cancer risk factors. Cancer. 1989;44:399–409.Google Scholar
- 22.Mosimann S, Torhorst JKH, Weber W, Muller H. Histopathological aspects of familial breast cancer. In: Weber W, Laffer UT, Durig M, editors. Hereditary cancer and preventive surgery. Karger: Basel; 1990. p 1–7.Google Scholar
- 28.O’Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol. 2009;27:18s (suppl; abstr 3).Google Scholar
- 41.Lynch HT, Snyder C, Lynch J, Ghate S, Thome S. Family information service (FIS) in a BRCA1 extended family (abstract). J Clin Oncol. 2006;24:55s.Google Scholar